{"schema_version":"1.0","type":"article","title":"Ivonescimab 跨出肺癌！正面挑戰膽道癌金標準，總生存期告捷","url":"https://drugnews.com.tw/articles/2026-09-04-ivonescimab-biliary-tract-cancer-harmoni-gi1.html","markdown_url":"https://drugnews.com.tw/articles/2026-09-04-ivonescimab-biliary-tract-cancer-harmoni-gi1.md","lang":"zh-Hant","date":"2026-09-04","publish_at":"2026-09-04T08:00:00+08:00","updated_at":"2026-09-04","category":"商業分析系列","topic":"商業分析系列","tags":["Ivonescimab","HARMONi-GI1","膽道癌","康方生物","Summit Therapeutics","Durvalumab","PD-1 VEGF 雙抗","臨床三期"],"summary":"Ivonescimab 合併化療在一線晚期膽道癌三期 HARMONi-GI1 達到總生存期主要終點，正面勝過 durvalumab 合併化療；完整風險比、生存曲線、安全性與亞組數據仍待公布。","key_points":[],"facts":[],"sections":["🩺 01｜膽道癌的難，不只在於病人少","⚔️ 02｜這場「頭對頭」，到底比了什麼？","🧬 03｜為什麼一支雙抗，可能和兩支藥聯用不同？","🥊 04｜康方為什麼總愛挑最難的對手？","🧭 05｜從一款肺癌藥，走向一個泛癌種平台？","💰 06｜對康方、Summit 與阿斯特捷利康，分別意味著什麼？","🏥 07｜如果完整數據夠強，臨床現場會怎麼變？","📊 08｜下一站，不是掌聲，而是五張成績單","資料來源"],"references":[],"images":[{"alt":"Facebook 原圖 1｜Ivonescimab 從肺癌跨向膽道癌","url":"https://drugnews.com.tw/assets/articles/ivonescimab-biliary-tract-cancer-harmoni-gi1/facebook-01.png"},{"alt":"Facebook 原圖 2｜HARMONi-GI1 三期已知結果與待公布數據","url":"https://drugnews.com.tw/assets/articles/ivonescimab-biliary-tract-cancer-harmoni-gi1/facebook-02.png"},{"alt":"Facebook 原圖 3｜PD-1 與 VEGF 四價雙特異性抗體機制","url":"https://drugnews.com.tw/assets/articles/ivonescimab-biliary-tract-cancer-harmoni-gi1/facebook-03.png"},{"alt":"Facebook 原圖 4｜從中國三期陽性到全球商業價值的驗證路徑","url":"https://drugnews.com.tw/assets/articles/ivonescimab-biliary-tract-cancer-harmoni-gi1/facebook-04.png"}],"cover_image":"https://drugnews.com.tw/assets/articles/ivonescimab-biliary-tract-cancer-harmoni-gi1/cover.png","publisher":{"name":"Drugnews｜藥時事","url":"https://drugnews.com.tw/","profile":"https://drugnews.com.tw/brand-profile.json"},"citation":"Drugnews｜藥時事（2026-09-04）。Ivonescimab 跨出肺癌！正面挑戰膽道癌金標準，總生存期告捷。https://drugnews.com.tw/articles/2026-09-04-ivonescimab-biliary-tract-cancer-harmoni-gi1.html","disclaimer":"本文僅供產業研究與知識分享，不構成投資、醫療、募資或個股建議。","translations":{"en":"2026-09-04-ivonescimab-biliary-tract-cancer-harmoni-gi1-en.html"},"relationship":"independent_editorial","disclosure_url":"https://drugnews.com.tw/policy/"}